Effect of methylprednisolone in cervical spinal cord injury stratified by injury severity: analysis in 908 patients.

Abstract

Study designCohort study.ObjectivesAlthough the effectiveness of methylprednisolone sodium succinate (MPSS) in spinal cord injury (SCI) is controversial, it is hypothesized that the effectiveness and safety profile of MPSS may vary in select cervical SCI sub-populations. The objective of this study is to clarify the effect of MPSS and its impact on adverse events in patients with cervical SCI, stratified by baseline neurological status.SettingThree large prospective, multicenter data sets of patients with acute SCI.MethodsPatients with acute cervical SCI were enrolled. The primary outcomes were upper extremity motor scores (UEMS) and lower extremity motor scores (LEMS) at 1 year. Patients were grouped by baseline American Spinal Injury Association Impairment Scale (AIS) grade.Results908 patients meeting inclusion criteria were analyzed. In AIS grade A patients, the use of MPSS resulted in significantly improved LEMS (mean difference [MD], 3.0; 95% CI, 0.3-5.6; p = 0.02), but not UEMS (MD, 0.5; 95% CI, -2.5-3.5; p = 0.74), at 1 year. In contrast, no significant benefit was observed in patients with AIS grades B, C, or D. In AIS grade A patients, the MPSS group had a lower incidence of cardiopulmonary adverse events (42.5 vs. 62.8%; p < 0.001) and gastrointestinal/genitourinary adverse events (13.7 vs. 22.4%; p = 0.04).ConclusionsMPSS was associated with improved lower extremity motor recovery in AIS grade A cervical SCI patients. No significant effect was seen in patients with incomplete injuries. MPSS was not associated with an overall increase in adverse events, suggesting it may be selectively beneficial in severe cervical SCI.